CL2013003306A1 - Uso de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, un tautómero o sal de la misma para preparar un medicamento útil para el tratamiento de carcinoma adenoide quístico. - Google Patents

Uso de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, un tautómero o sal de la misma para preparar un medicamento útil para el tratamiento de carcinoma adenoide quístico.

Info

Publication number: CL2013003306A1
Authority: CL; Chile
Prior art keywords: benzimidazol; quinolin; tautomer; piperazin; fluoro
Prior art date: 2011-05-19

Application number

CL2013003306A

Other languages

English (en)

Inventor

Michael Shi

Michael Wick

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-05-19

Filing date

2013-11-18

Publication date

2014-07-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46168643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013003306(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-11-18 Application filed by Novartis Ag filed Critical Novartis Ag

2014-07-11 Publication of CL2013003306A1 publication Critical patent/CL2013003306A1/es

Links

208000002517 adenoid cystic carcinoma Diseases 0.000 title 1
PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 title 1
239000003814 drug Substances 0.000 title 1
229940079593 drug Drugs 0.000 title 1
201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

CL2013003306A 2011-05-19 2013-11-18 Uso de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, un tautómero o sal de la misma para preparar un medicamento útil para el tratamiento de carcinoma adenoide quístico. CL2013003306A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161487939P	2011-05-19	2011-05-19

Publications (1)

Publication Number	Publication Date
CL2013003306A1 true CL2013003306A1 (es)	2014-07-11

Family

ID=46168643

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013003306A CL2013003306A1 (es)	2011-05-19	2013-11-18	Uso de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, un tautómero o sal de la misma para preparar un medicamento útil para el tratamiento de carcinoma adenoide quístico.

Country Status (18)

Country	Link
US (1)	US20150182525A1 (es)
EP (1)	EP2709729A1 (es)
JP (1)	JP2014515353A (es)
KR (1)	KR20140023358A (es)
CN (1)	CN103547315A (es)
AU (1)	AU2012255148A1 (es)
BR (1)	BR112013029246A2 (es)
CA (1)	CA2834699A1 (es)
CL (1)	CL2013003306A1 (es)
IL (1)	IL229073A0 (es)
MA (1)	MA35156B1 (es)
MX (1)	MX2013013437A (es)
PH (1)	PH12013502099A1 (es)
RU (1)	RU2013156378A (es)
SG (1)	SG194445A1 (es)
TN (1)	TN2013000414A1 (es)
WO (1)	WO2012158994A1 (es)
ZA (1)	ZA201307411B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
RS58514B1 (sr)	2012-06-13	2019-04-30	Incyte Holdings Corp	Supstituisana triciklična jedinjenja kao inhibitori fgfr
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
PE20150964A1 (es)	2012-09-07	2015-07-25	Coherus Biosciences Inc	Formulaciones acuosas estables de adalimumab
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
PH12015502383B1 (en)	2013-04-19	2023-02-03	Incyte Holdings Corp	Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en)	2015-02-20	2017-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
TWI712601B (zh)	2015-02-20	2020-12-11	美商英塞特公司	作為fgfr抑制劑之雙環雜環
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US11229702B1 (en)	2015-10-28	2022-01-25	Coherus Biosciences, Inc.	High concentration formulations of adalimumab
US9782370B2 (en) *	2015-12-21	2017-10-10	Gongwin Biopharm Holdings Co., Ltd.	Pharmaceutical compositions of benzenesulfonamide derivatives for treatment of adenoid cystic carcinoma
US11071782B2 (en)	2016-04-20	2021-07-27	Coherus Biosciences, Inc.	Method of filling a container with no headspace
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
HRP20241288T1 (hr)	2018-05-04	2024-12-06	Incyte Corporation	Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
AU2019262579B2 (en)	2018-05-04	2024-09-12	Incyte Corporation	Salts of an FGFR inhibitor
US11628162B2 (en)	2019-03-08	2023-04-18	Incyte Corporation	Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
CA3157361A1 (en)	2019-10-14	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
CA3163875A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
JP7832891B2 (ja)	2019-12-04	2026-03-18	インサイト・コーポレイション	Ｆｇｆｒ阻害剤の誘導体
US12012409B2 (en)	2020-01-15	2024-06-18	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US12115140B2 (en) *	2020-07-31	2024-10-15	The Trustees Of Columbia University In The City Of New York	Method of treating adenoid cystic carcinoma
WO2022221170A1 (en)	2021-04-12	2022-10-20	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220155A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
US11939331B2 (en)	2021-06-09	2024-03-26	Incyte Corporation	Tricyclic heterocycles as FGFR inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60115069T2 (de)	2000-09-11	2006-08-03	Chiron Corp., Emeryville	Chinolinonderivate als tyrosin-kinase inhibitoren
EP1539754A4 (en)	2002-08-23	2009-02-25	Novartis Vaccines & Diagnostic	BENZIMIDAZOCHINOLINONE AND ITS USE
EP2301546B1 (en) *	2005-01-27	2014-09-10	Novartis AG	Treatment of metastasized tumors
EP1885187B1 (en) *	2005-05-13	2013-09-25	Novartis AG	Methods for treating drug resistant cancer
BRPI0611375A2 (pt)	2005-05-23	2010-08-31	Novartis Ag	formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
EP2083081A1 (en)	2005-07-22	2009-07-29	Five Prime Therapeutics, Inc.	Compositions and methods of treating disease with FGFR fusion proteins
PE20091628A1 (es)	2008-03-19	2009-11-19	Novartis Ag	Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
CN102834094B (zh) *	2010-04-16	2015-05-06	诺华有限公司	有机化合物的组合产品及其制药用途

2012
- 2012-05-18 MX MX2013013437A patent/MX2013013437A/es unknown
- 2012-05-18 PH PH1/2013/502099A patent/PH12013502099A1/en unknown
- 2012-05-18 WO PCT/US2012/038490 patent/WO2012158994A1/en not_active Ceased
- 2012-05-18 CA CA2834699A patent/CA2834699A1/en not_active Abandoned
- 2012-05-18 AU AU2012255148A patent/AU2012255148A1/en not_active Abandoned
- 2012-05-18 JP JP2014511568A patent/JP2014515353A/ja active Pending
- 2012-05-18 BR BR112013029246A patent/BR112013029246A2/pt not_active IP Right Cessation
- 2012-05-18 KR KR1020137030212A patent/KR20140023358A/ko not_active Withdrawn
- 2012-05-18 US US14/117,057 patent/US20150182525A1/en not_active Abandoned
- 2012-05-18 EP EP12723801.2A patent/EP2709729A1/en not_active Withdrawn
- 2012-05-18 SG SG2013075270A patent/SG194445A1/en unknown
- 2012-05-18 CN CN201280023953.9A patent/CN103547315A/zh active Pending
- 2012-05-18 RU RU2013156378/15A patent/RU2013156378A/ru unknown
2013
- 2013-10-04 ZA ZA2013/07411A patent/ZA201307411B/en unknown
- 2013-10-11 TN TNP2013000414A patent/TN2013000414A1/fr unknown
- 2013-10-24 IL IL229073A patent/IL229073A0/en unknown
- 2013-11-15 MA MA36443A patent/MA35156B1/fr unknown
- 2013-11-18 CL CL2013003306A patent/CL2013003306A1/es unknown

Also Published As

Publication number	Publication date
AU2012255148A1 (en)	2013-11-07
BR112013029246A2 (pt)	2017-02-14
JP2014515353A (ja)	2014-06-30
MX2013013437A (es)	2013-12-06
MA35156B1 (fr)	2014-06-02
ZA201307411B (en)	2014-06-25
EP2709729A1 (en)	2014-03-26
CA2834699A1 (en)	2012-11-22
CN103547315A (zh)	2014-01-29
KR20140023358A (ko)	2014-02-26
WO2012158994A1 (en)	2012-11-22
US20150182525A1 (en)	2015-07-02
IL229073A0 (en)	2013-12-31
SG194445A1 (en)	2013-12-30
RU2013156378A (ru)	2015-06-27
NZ616345A (en)	2015-10-30
TN2013000414A1 (en)	2015-03-30
PH12013502099A1 (en)	2017-10-25

Similar Documents

Publication	Publication Date	Title
CL2013003306A1 (es)	2014-07-11	Uso de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, un tautómero o sal de la misma para preparar un medicamento útil para el tratamiento de carcinoma adenoide quístico.
NO2025022I1 (no)	2025-05-12	Belzutifan, or a pharmaceutically acceptable salt thereof, particularly belzutifan.
BR112015003376A2 (pt)	2017-07-04	composto ou sal farmaceuticamente aceitável do mesmo , composição farmacêutica e usos de quantidade eficiente
IL235607A0 (en)	2015-01-29	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
LT3447061T (lt)	2022-01-25	Farmacinė vaisto forma, apimanti 5-fluor-2'-deoksiuridinofosforamidato darinį, skirtą naudoti vėžio gydymui
SI3129355T1 (sl)	2019-03-29	Fungicidni derivati N'-(2-metil-6-(2-alkoksi-etoksi)-3-piridil)-N-alkil-formamida za uporabo v poljedelstvu
BR112015003397A2 (pt)	2019-09-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
CL2014002873A1 (es)	2015-04-24	Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
LT3026064T (lt)	2019-01-25	Antikūnai, skirti vėžio gydymui, ekspresuojantys klaudiną 6
PT4000608T (pt)	2026-03-05	Composição farmacêutica, métodos para o tratamento e suas utilizações
BR112015002524A2 (pt)	2017-07-04	derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças.
PL3871515T3 (pl)	2025-06-16	Sole nikotyny, ko-kryształy i kompleksy ko-kryształów soli
CL2014001988A1 (es)	2014-11-03	Un compuesto 5-(4-ciclopropil-1h-imidazol-1-il)-n-(6-(4-isopropil-4h-1,2,4-triazol-3-il)piridin-2-il)-2-fluoro-4-metilbenzamida o sus sales, como inhibidores de la quinasa reguladora de la señal de apoptosis; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento de la enfermedad renal cronica, nefropatia diabetica, fibrosis renal, entre otras.
BR112014028424A2 (pt)	2018-04-24	compostos de pirimidina para o tratamento de câncer
PT2838539T (pt)	2017-11-15	Derivados estrogénicos para utilização no tratamento de distúrbios neurológicos.
BR212014030074U2 (pt)	2017-06-13	segmento de filtro para um artigo para fumar , artigo para fumar.
LT2945642T (lt)	2024-06-25	Faktoriaus 1 baltymas, skirtas naudoti ligų gydymui arba prevencijai
PL2872497T3 (pl)	2017-07-31	Pochodne chromanylowe do leczenia choroby mitochondrialnej
SI3069720T1 (sl)	2020-02-28	Farmacevtski sestavek, ki vsebuje derivate glutarimida, in njegova uporaba za zdravljenje eozinofilnih bolezni
BR112014031635A2 (pt)	2017-06-27	derivados de pró-fármaco de (e)-n-metil-n-( (3-metilbenzofuran-2-il) metil)-3-(7-oxo-5,6,7,8-tetraidro- 1, 8- naftirindin-3-il) acrilamida
CL2013003230A1 (es)	2014-08-01	Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de tumores sólidos avanzados y/o metastásicos.
BR112014027814A2 (pt)	2017-06-27	agentes sinérgicos antimicrobianos.
BR112014030159A2 (pt)	2017-06-27	agente para tratamento de floculação.
LTPA2020511I1 (lt)	2020-07-27	Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui
CL2013003198A1 (es)	2014-06-20	Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de malignidades sólidas que incluyen malignidades sólidas avanzadas y metastásicas.